Ageing populations and emerging market demand look set to cement the pharmaceutical industry’s attractions as a prime portfolio proposition, despite Western governments’ spending cuts. Mark Dunne investigates and concludes investors can look to the UK and beyond to get a share of the spoils.
We use cookies to ensure that we give you the best experience on our website.
If you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website.
You may change your preferences at any time.
